FDA Actions, Economy Affect Biotech Industry

Increased scrutiny by federal drug regulators and continued mergers and acquisitions activity could curb expansion in biotechnology and pharmaceutical industries, according to analysts and economists. A capacity constraint caused by a shortage of manufacturing facilities also could chill the overheated biotech market and job growth as companies exhaust their three-year funding cycles in the next few years, cautions Robert Toth, portfolio manager of the medical technology fund of EGM Capital in S

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

"There is no FDA commissioner, no champion for the agency right now," Toth says. "For the first time in four years, in 2000 the FDA spent a long time in reviewing and approving new drugs. It was a pretty dramatic slippage. Biotechs, in particular, depend on rapid drug approvals from the FDA, because they do not have the large cash reserves to finance lengthy drug discoveries, according to Toth. The biotechs are affected to a greater degree than the big pharma companies, [because] they tend to try and get their drugs approved on less data."

Once a drug has been approved, companies can easily spend $250 million or more to build production facilities, and investors are reluctant to provide the funding until the approval is assured. Meanwhile, both big pharma and small biotech companies continue on the mergers and acquisitions track in the race to overtake their competitors in AIDS, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Peg Brickley

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide